-
1
-
-
42949119819
-
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
-
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105(8):2812–2817
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.8
, pp. 2812-2817
-
-
Aerts, J.M.1
Groener, J.E.2
Kuiper, S.3
Donker-Koopman, W.E.4
Strijland, A.5
Ottenhoff, R.6
van Roomen, C.7
Mirzaian, M.8
Wijburg, F.A.9
Linthorst, G.E.10
Vedder, A.C.11
Rombach, S.M.12
Cox-Brinkman, J.13
Somerharju, P.14
Boot, R.G.15
Hollak, C.E.16
Brady, R.O.17
Poorthuis, B.J.18
-
2
-
-
79959803398
-
Biomarkers in the diagnosis of lysosomal storage disorders: Proteins, lipids, and inhibodies
-
Aerts JM, Kallemeijn WW, Wegdam W, Joao Ferraz M, van Breemen MJ, Dekker N, Kramer G, Poorthuis BJ, Groener JE, Cox-Brinkman J, Rombach SM, Hollak CE, Linthorst GE, Witte MD, Gold H, van der Marel GA, Overkleeft HS, Boot RG (2011) Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis 34:605–619
-
(2011)
J Inherit Metab Dis
, vol.34
, pp. 605-619
-
-
Aerts, J.M.1
Kallemeijn, W.W.2
Wegdam, W.3
Joao Ferraz, M.4
van Breemen, M.J.5
Dekker, N.6
Kramer, G.7
Poorthuis, B.J.8
Groener, J.E.9
Cox-Brinkman, J.10
Rombach, S.M.11
Hollak, C.E.12
Linthorst, G.E.13
Witte, M.D.14
Gold, H.15
van der Marel, G.A.16
Overkleeft, H.S.17
Boot, R.G.18
-
3
-
-
33846908304
-
Agalsidase-beta therapy for advanced Fabry disease: A randomized trial
-
Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146(2):77–86
-
(2007)
Ann Intern Med
, vol.146
, Issue.2
, pp. 77-86
-
-
Banikazemi, M.1
Bultas, J.2
Waldek, S.3
Wilcox, W.R.4
Whitley, C.B.5
McDonald, M.6
Finkel, R.7
Packman, S.8
Bichet, D.G.9
Warnock, D.G.10
Desnick, R.J.11
-
4
-
-
0036016096
-
Agalsidase alfa–a preparation for enzyme replacement therapy in Anderson-Fabry disease
-
Beck M (2002) Agalsidase alfa–a preparation for enzyme replacement therapy in Anderson-Fabry disease. Expert Opin Investig Drugs 11(6):851–858
-
(2002)
Expert Opin Investig Drugs
, vol.11
, Issue.6
, pp. 851-858
-
-
Beck, M.1
-
5
-
-
57449085309
-
A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease
-
Benichou B, Goyal S, Sung C, Norfleet AM, O'Brien F (2009) A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 96(1):4–12
-
(2009)
Mol Genet Metab
, vol.96
, Issue.1
, pp. 4-12
-
-
Benichou, B.1
Goyal, S.2
Sung, C.3
Norfleet, A.M.4
O'brien, F.5
-
6
-
-
0036984003
-
Pain assessment: The advantages of using pain scales in lysosomal storage diseases
-
Cleeland CS (2002) Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl 91(439):43–47
-
(2002)
Acta Paediatr Suppl
, vol.91
, Issue.439
, pp. 43-47
-
-
Cleeland, C.S.1
-
7
-
-
37449013735
-
Depression in adults with Fabry disease: A common and under-diagnosed problem
-
Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH (2007) Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 30(6):943–951
-
(2007)
J Inherit Metab Dis
, vol.30
, Issue.6
, pp. 943-951
-
-
Cole, A.L.1
Lee, P.J.2
Hughes, D.A.3
Deegan, P.B.4
Waldek, S.5
Lachmann, R.H.6
-
9
-
-
0035811624
-
Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry's disease
-
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry's disease. N Engl J Med 345(1):9–16
-
(2001)
N Engl J Med
, vol.345
, Issue.1
, pp. 9-16
-
-
Eng, C.M.1
Guffon, N.2
Wilcox, W.R.3
Germain, D.P.4
Lee, P.5
Waldek, S.6
Caplan, L.7
Linthorst, G.E.8
Desnick, R.J.9
-
10
-
-
59449103189
-
Disease-specific health-related quality of life questionnaires for heart failure: A systematic review with meta-analyses
-
Garin O, Ferrer M, Pont A, Rue M, Kotzeva A, Wiklund I, Van Ganse E, Alonso J (2009) Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res 18(1):71–85
-
(2009)
Qual Life Res
, vol.18
, Issue.1
, pp. 71-85
-
-
Garin, O.1
Ferrer, M.2
Pont, A.3
Rue, M.4
Kotzeva, A.5
Wiklund, I.6
van Ganse, E.7
Alonso, J.8
-
11
-
-
76549116109
-
A validated disease severity scoring system for Fabry disease
-
Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A (2010) A validated disease severity scoring system for Fabry disease. Mol Genet Metab 99(3):283–290
-
(2010)
Mol Genet Metab
, vol.99
, Issue.3
, pp. 283-290
-
-
Giannini, E.H.1
Mehta, A.B.2
Hilz, M.J.3
Beck, M.4
Bichet, D.G.5
Brady, R.O.6
West, M.7
Germain, D.P.8
Wanner, C.9
Waldek, S.10
Clarke, J.T.11
Mengel, E.12
Strotmann, J.M.13
Warnock, D.G.14
Linhart, A.15
-
12
-
-
0036260323
-
Quality of life of patients with Fabry disease
-
Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, Pashos CL (2002) Quality of life of patients with Fabry disease. Qual Life Res 11(4):317–327
-
(2002)
Qual Life Res
, vol.11
, Issue.4
, pp. 317-327
-
-
Gold, K.F.1
Pastores, G.M.2
Botteman, M.F.3
Yeh, J.M.4
Sweeney, S.5
Aliski, W.6
Pashos, C.L.7
-
13
-
-
15044357727
-
Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: Data from FOS (Fabry Outcome Survey)
-
Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R (2005) Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 42(3):247–252
-
(2005)
J Med Genet
, vol.42
, Issue.3
, pp. 247-252
-
-
Hoffmann, B.1
Garcia de Lorenzo, A.2
Mehta, A.3
Beck, M.4
Widmer, U.5
Ricci, R.6
-
14
-
-
33947316741
-
Agalsidase Beta: A review of its use in the management of Fabry disease
-
Keating GM, Simpson D (2007) Agalsidase Beta: a review of its use in the management of Fabry disease. Drugs 67(3):435–455
-
(2007)
Drugs
, vol.67
, Issue.3
, pp. 435-455
-
-
Keating, G.M.1
Simpson, D.2
-
15
-
-
0013192938
-
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease
-
Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, Geagan L, Qiu H, Seiger K, Barngrover D, McPherson JM, Edmunds T (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13(4):305–313
-
(2003)
Glycobiology
, vol.13
, Issue.4
, pp. 305-313
-
-
Lee, K.1
Jin, X.2
Zhang, K.3
Copertino, L.4
Andrews, L.5
Baker-Malcolm, J.6
Geagan, L.7
Qiu, H.8
Seiger, K.9
Barngrover, D.10
McPherson, J.M.11
Edmunds, T.12
-
16
-
-
4644316602
-
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
-
Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66(4):1589–1595
-
(2004)
Kidney Int
, vol.66
, Issue.4
, pp. 1589-1595
-
-
Linthorst, G.E.1
Hollak, C.E.2
Donker-Koopman, W.E.3
Strijland, A.4
Aerts, J.M.5
-
17
-
-
85060699364
-
Guidelines for the treatment of Fabry Disease through the Life Saving Drugs Program
-
LSDP (2010) Guidelines for the treatment of Fabry Disease through the Life Saving Drugs Program, August 2010
-
(2010)
August
-
-
-
18
-
-
70349316414
-
Evaluation of low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease
-
Lubanda JC, Anijalg E, Bzduch V, Thurberg BL, Benichou B, Tylki-Szymanska A (2009) Evaluation of low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 11(4): 256–264
-
(2009)
Genet Med
, vol.11
, Issue.4
, pp. 256-264
-
-
Lubanda, J.C.1
Anijalg, E.2
Bzduch, V.3
Thurberg, B.L.4
Benichou, B.5
Tylki-Szymanska, A.6
-
19
-
-
71649111830
-
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: An analysis of registry data
-
Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374(9706):1986–1996
-
(2009)
Lancet
, vol.374
, Issue.9706
, pp. 1986-1996
-
-
Mehta, A.1
Beck, M.2
Elliott, P.3
Giugliani, R.4
Linhart, A.5
Sunder-Plassmann, G.6
Schiffmann, R.7
Barbey, F.8
Ries, M.9
Clarke, J.T.10
-
20
-
-
0036240872
-
Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention
-
Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD (2002) Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res 11(2):127–133
-
(2002)
Qual Life Res
, vol.11
, Issue.2
, pp. 127-133
-
-
Miners, A.H.1
Holmes, A.2
Sherr, L.3
Jenkinson, C.4
Macdermot, K.D.5
-
21
-
-
34848819423
-
Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy
-
Ohashi T, Sakuma M, Kitagawa T, Suzuki K, Ishige N, Eto Y (2007) Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab 92(3):271–273
-
(2007)
Mol Genet Metab
, vol.92
, Issue.3
, pp. 271-273
-
-
Ohashi, T.1
Sakuma, M.2
Kitagawa, T.3
Suzuki, K.4
Ishige, N.5
Eto, Y.6
-
22
-
-
44649172457
-
Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease
-
Ohashi T, Iizuka S, Ida H, Eto Y (2008) Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol Genet Metab 94(3):313–318
-
(2008)
Mol Genet Metab
, vol.94
, Issue.3
, pp. 313-318
-
-
Ohashi, T.1
Iizuka, S.2
Ida, H.3
Eto, Y.4
-
23
-
-
0035949059
-
Enzyme-replacement therapy for Anderson-Fabry disease
-
Pastores GM, Thadhani R (2001) Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 358(9282):601–603
-
(2001)
Lancet
, vol.358
, Issue.9282
, pp. 601-603
-
-
Pastores, G.M.1
Thadhani, R.2
-
24
-
-
34547830275
-
Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease
-
Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N (2007) Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 22(7):1920–1925
-
(2007)
Nephrol Dial Transplant
, vol.22
, Issue.7
, pp. 1920-1925
-
-
Pastores, G.M.1
Boyd, E.2
Crandall, K.3
Whelan, A.4
Piersall, L.5
Barnett, N.6
-
25
-
-
33749067655
-
Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease
-
Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118(3): 924–932
-
(2006)
Pediatrics
, vol.118
, Issue.3
, pp. 924-932
-
-
Ries, M.1
Clarke, J.T.2
Whybra, C.3
Timmons, M.4
Robinson, C.5
Schlaggar, B.L.6
Pastores, G.7
Lien, Y.H.8
Kampmann, C.9
Brady, R.O.10
Beck, M.11
Schiffmann, R.12
-
26
-
-
77954959657
-
Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease
-
Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd Bergh Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM (2010) Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802(9):741–748
-
(2010)
Biochim Biophys Acta
, vol.1802
, Issue.9
, pp. 741-748
-
-
Rombach, S.M.1
Dekker, N.2
Bouwman, M.G.3
Linthorst, G.E.4
Zwinderman, A.H.5
Wijburg, F.A.6
Kuiper, S.7
Vd Bergh Weerman, M.A.8
Groener, J.E.9
Poorthuis, B.J.10
Hollak, C.E.11
Aerts, J.M.12
-
27
-
-
33645218156
-
Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice
-
Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T, Chiba Y, Takashiba M, Jigami Y, Fukushige T, Kanzaki T, Itoh K (2006) Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 51(3):180–188
-
(2006)
J Hum Genet
, vol.51
, Issue.3
, pp. 180-188
-
-
Sakuraba, H.1
Murata-Ohsawa, M.2
Kawashima, I.3
Tajima, Y.4
Kotani, M.5
Ohshima, T.6
Chiba, Y.7
Takashiba, M.8
Jigami, Y.9
Fukushige, T.10
Kanzaki, T.11
Itoh, K.12
-
28
-
-
70350509103
-
Enzyme replacement therapy for Fabry disease: A systematic review of available evidence
-
Schaefer RM, Tylki-Szymanska A, Hilz MJ (2009) Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 69(16):2179–2205
-
(2009)
Drugs
, vol.69
, Issue.16
, pp. 2179-2205
-
-
Schaefer, R.M.1
Tylki-Szymanska, A.2
Hilz, M.J.3
-
29
-
-
0035816007
-
Enzyme replacement therapy in Fabry disease: A randomized controlled trial
-
Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743–2749
-
(2001)
JAMA
, vol.285
, Issue.21
, pp. 2743-2749
-
-
Schiffmann, R.1
Kopp, J.B.2
Austin, H.A.3
Sabnis, S.4
Moore, D.F.5
Weibel, T.6
Balow, J.E.7
Brady, R.O.8
-
30
-
-
31544456336
-
Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting
-
Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21(2):345–354
-
(2006)
Nephrol Dial Transplant
, vol.21
, Issue.2
, pp. 345-354
-
-
Schiffmann, R.1
Ries, M.2
Timmons, M.3
Flaherty, J.T.4
Brady, R.O.5
-
31
-
-
34248138939
-
Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing
-
Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, Ries M (2007) Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18(5): 1576–1583
-
(2007)
J am Soc Nephrol
, vol.18
, Issue.5
, pp. 1576-1583
-
-
Schiffmann, R.1
Askari, H.2
Timmons, M.3
Robinson, C.4
Benko, W.5
Brady, R.O.6
Ries, M.7
-
32
-
-
77953021876
-
Plasma globotriaosylsphingosine as a biomarker of Fabry disease
-
Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H (2010) Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 100(3):257–261
-
(2010)
Mol Genet Metab
, vol.100
, Issue.3
, pp. 257-261
-
-
Togawa, T.1
Kodama, T.2
Suzuki, T.3
Sugawara, K.4
Tsukimura, T.5
Ohashi, T.6
Ishige, N.7
Suzuki, K.8
Kitagawa, T.9
Sakuraba, H.10
-
33
-
-
44949167697
-
Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy
-
Torra R, Algaba F, Ars E, Santin S, Fernandez-Llama P, Ballarin J (2008) Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy. Clin Nephrol 69(6): 445–449
-
(2008)
Clin Nephrol
, vol.69
, Issue.6
, pp. 445-449
-
-
Torra, R.1
Algaba, F.2
Ars, E.3
Santin, S.4
Fernandez-Llama, P.5
Ballarin, J.6
-
34
-
-
78650275925
-
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy
-
van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, Breunig F, Wanner C, Aerts JM, Hollak CE (2011) Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812(1):70–76
-
(2011)
Biochim Biophys Acta
, vol.1812
, Issue.1
, pp. 70-76
-
-
van Breemen, M.J.1
Rombach, S.M.2
Dekker, N.3
Poorthuis, B.J.4
Linthorst, G.E.5
Zwinderman, A.H.6
Breunig, F.7
Wanner, C.8
Aerts, J.M.9
Hollak, C.E.10
-
35
-
-
39549116083
-
Treatment of Fabry disease: Outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg
-
Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2(7):e598
-
(2007)
Plos One
, vol.2
, Issue.7
-
-
Vedder, A.C.1
Linthorst, G.E.2
Houge, G.3
Groener, J.E.4
Ormel, E.E.5
Bouma, B.J.6
Aerts, J.M.7
Hirth, A.8
Hollak, C.E.9
-
36
-
-
44949248124
-
Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3
-
Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, Ten Berge IJ, Groener JE, Aerts JM, Wanner C, Hollak CE (2008) Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 94(3):319–325
-
(2008)
Mol Genet Metab
, vol.94
, Issue.3
, pp. 319-325
-
-
Vedder, A.C.1
Breunig, F.2
Donker-Koopman, W.E.3
Mills, K.4
Young, E.5
Winchester, B.6
Ten Berge, I.J.7
Groener, J.E.8
Aerts, J.M.9
Wanner, C.10
Hollak, C.E.11
-
37
-
-
78649565697
-
Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
-
Watt T, Burlina AP, Cazzorla C, Schonfeld D, Banikazemi M, Hopkin RJ, Martins AM, Sims K, Beitner-Johnson D, O'Brien F, Feldt-Rasmussen U (2010) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med 12(11): 703–712
-
(2010)
Genet Med
, vol.12
, Issue.11
, pp. 703-712
-
-
Watt, T.1
Burlina, A.P.2
Cazzorla, C.3
Schonfeld, D.4
Banikazemi, M.5
Hopkin, R.J.6
Martins, A.M.7
Sims, K.8
Beitner-Johnson, D.9
O'brien, F.10
Feldt-Rasmussen, U.11
-
38
-
-
11144358101
-
The Mainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy
-
Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307
-
(2004)
Clin Genet
, vol.65
, Issue.4
, pp. 299-307
-
-
Whybra, C.1
Kampmann, C.2
Krummenauer, F.3
Ries, M.4
Mengel, E.5
Miebach, E.6
Baehner, F.7
Kim, K.8
Bajbouj, M.9
Schwarting, A.10
Gal, A.11
Beck, M.12
-
39
-
-
68049134975
-
A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease
-
Whybra C, Miebach E, Mengel E, Gal A, Baron K, Beck M, Kampmann C (2009) A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 11(6):441–449
-
(2009)
Genet Med
, vol.11
, Issue.6
, pp. 441-449
-
-
Whybra, C.1
Miebach, E.2
Mengel, E.3
Gal, A.4
Baron, K.5
Beck, M.6
Kampmann, C.7
-
40
-
-
3142554529
-
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease
-
Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75(1):65–74
-
(2004)
Am J Hum Genet
, vol.75
, Issue.1
, pp. 65-74
-
-
Wilcox, W.R.1
Banikazemi, M.2
Guffon, N.3
Waldek, S.4
Lee, P.5
Linthorst, G.E.6
Desnick, R.J.7
Germain, D.P.8
-
41
-
-
16844377475
-
Is globotriaosylceramide a useful biomarker in Fabry disease?
-
discussion 37–58
-
Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, Winchester B (2005) Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 94(447):51–54, discussion 37–58
-
(2005)
Acta Paediatr Suppl
, vol.94
, Issue.447
, pp. 51-54
-
-
Young, E.1
Mills, K.2
Morris, P.3
Vellodi, A.4
Lee, P.5
Waldek, S.6
Winchester, B.7
|